Longevity & AgingReview ArticleOpen Access

Does the Body's Growth Brake Never Switch Off and Quietly Drive Aging

A century-old idea gets a modern update: the signals that stop growth in youth may keep running in adulthood, shrinking our tissues as we age.

Saturday, November 14, 2026 1 view
Published in Philos Trans R Soc Lond B Biol Sci
Side-by-side MRI brain scans of a young adult and an elderly person showing shrinkage and enlarged ventricles on a light box

Summary

Why do we age? This review revives a 100-year-old hypothesis from biologist Bidder: the same internal brake that slows growth and sets adult body size never switches off. Instead, it keeps pressing, so tissues eventually make less than they lose and slowly shrink. The authors lay out how this could explain organ atrophy, and they gather supporting clues. Larger animals tend to live longer. Many human organs lose cells and mass with age. Protein and RNA production fall across the body. They also note what is still unknown, including how growth is regulated and where the model fails. It is a framework to test, not a proven cause, but it could shape how future anti-aging treatments are designed.

Detailed Summary

Despite decades of research, the root causes of aging are unresolved. Theories split into damage-based models, which dominate current work, and program-based models. Program-based models propose either that aging evolved for an adaptive purpose or that it results from evolutionary neglect, such as developmental processes continuing beyond their optimal window. Viegas and de Magalhães revisit a hypothesis proposed about a century ago by Bidder: the mechanism that slows growth and fixes adult body size keeps running after growth stops, and this continued action produces senescence.

The authors frame this as a lifelong growth-rate curve with three phases. In phase 1, growth is positive and accelerating. In phase 2, growth stays positive but decelerates until it reaches a renewal threshold, where production and degradation balance and net growth ceases. In phase 3, which is theoretical, sustained growth-restriction signaling pushes the rate below zero. Degradation then outpaces biosynthesis, causing net loss of cells and matrix, which is the atrophy seen in aging. Reduced stem and progenitor activity and falling biosynthesis in remaining cells could be amplified by vicious cycles.

How growth is regulated remains poorly understood. The GH/IGF1 axis explains only part of adult size, and growth slows in juveniles even when GH is high. Proposed frameworks include a negative-feedback model, in which growth itself downregulates growth-promoting genes, and the theory of organisms, which treats proliferation as the cellular default that multicellular life must constrain. Candidate mediators include Hippo, Wnt/beta-catenin, TGF-beta and bioelectric signals, stabilized by epigenetic changes. Comparative genomics, such as about 300 body-size-linked genes in Carnivora, is pointing to tumor-suppression and metabolic pathways.

The evidence is mostly correlational. Across mammals, birds and reptiles, larger species tend to live longer, with bats a notable exception, and slower development correlates with longer lifespan. Human data show atrophy in many tissues. Thymic involution begins around age 1. The brain loses volume and cells. Muscle loses fibers and fiber size. Marrow turns fatty, nephron number falls, the skin thins, the pancreas shrinks, and ovarian reserve declines continuously. GTEx histology shows rising atrophy and microvascular rarefaction, and high-turnover tissues lose the most functional mass. Proliferation markers fall in the colon, esophagus and duodenum.

Biosynthesis also appears to decline. Whole-body translation falls from development to old age, rRNA gene activity drops in aged skin fibroblasts, and mitochondrial translation declines in muscle. A transcriptomic meta-analysis suggests lower overall transcription, and aging signatures consistently show downregulated protein synthesis machinery. The authors also discuss experimental manipulation of growth-associated genes and growth factors, such as FGF21, that mitigates aging phenotypes.

The model has gaps. Phase 3 is an extrapolation rather than a measurement. The prostate grows with age, evidence for generalized cardiac atrophy is limited, and the liver is relatively resilient. Hyperplasia in some tissues may be a compensatory response. Proliferation is hard to measure in vivo, and Ki67 has limitations. The authors present this as a framework for future testing, one that links caloric restriction, GH-pathway mutations and rapamycin to growth regulation.

Key Findings

  • Proposes a three-phase lifelong growth-rate curve: accelerating growth, decelerating growth to a renewal threshold, and a theoretical negative-growth phase that equals atrophy
  • Atrophy is documented across about 20 human tissues, including brain, muscle, kidney, skin, pancreas, thymus, bone and ovary, though the prostate increases in size
  • Thymic involution begins very early in life, around 1 year of age in humans, with thymic cells replaced by adipose tissue
  • Whole-body translation rates decline from development to old age, and transcriptomic meta-analyses show consistent downregulation of protein synthesis machinery
  • Across mammals, birds and reptiles, larger species generally live longer and slower development correlates with longer lifespan, with bats as a notable exception
  • Comparative genomics in Carnivora linked about 300 genes to body size, enriched for metabolism, obesity, development and tumor suppression
  • Proliferating cells decline with age in high-turnover epithelia such as the colon, esophagus and duodenum, and GTEx data show rising atrophy and microvascular rarefaction

Methodology

This is a narrative, conceptual review rather than a systematic or quantitative analysis. The authors synthesize historical hypotheses (Bidder, Martin, Lui and Baron), comparative genomics, human tissue atrophy data summarized in a 22-organ table, biosynthesis measurements and gene manipulation studies. No new data, sample sizes or statistical tests are reported, and the lifelong growth-rate curve is a schematic. Note that the supplied text was cut off partway through the gene-manipulation section.

Study Limitations

The authors state that phase 3 (negative growth) is a theoretical extension of the growth trajectory and not directly measured, and that the mechanisms of growth regulation are still poorly understood. Evidence is largely correlational, tissue-specific exceptions exist (prostate, heart, liver), proliferation is hard to measure in vivo, and hyperplasia in some aging tissues may be compensatory. No conflicts of interest were visible in the supplied text.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: